Valeant Pharma (NYSE:VRX) Hold Rating Has Just Been Reiterated by BTIG

May 10, 2018 - By Dolores Ford

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Logo

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It worsened, as 51 investors sold Valeant Pharmaceuticals International, Inc. shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported.

Old Mutual Investors (Uk) Ltd has invested 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Quantitative Invest Mngmt holds 0.03% or 112,000 shares. Spark Investment Management Limited Liability Com, a New York-based fund reported 39,000 shares. Deutsche Financial Bank Ag reported 2.85M shares. Sigma Planning Corp reported 0.02% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). D E Shaw Com Incorporated invested in 638,072 shares or 0.02% of the stock. Us Natl Bank De invested in 16,969 shares. Royal Bancshares Of Canada holds 2.93 million shares. Cibc Asset Management Incorporated accumulated 124,559 shares or 0.02% of the stock. Moreover, Bridgewater Associate Limited Partnership has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 41,855 shares. Alphamark Limited Liability Corp accumulated 186 shares. City Holdings Company invested in 0% or 70 shares. Swiss Bank stated it has 0.03% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Cambridge Advisors owns 12,275 shares. Greatmark Investment Partners Incorporated accumulated 0.21% or 28,350 shares.

Since March 8, 2018, it had 3 insider buys, and 0 sales for $876,370 activity. 30,000 Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares with value of $481,500 were bought by PAPA JOSEPH C. 10,000 shares were bought by DE SCHUTTER RICHARD U, worth $153,400.

Valeant Pharma (NYSE:VRX) Rating Reaffirmed

BTIG maintained their Hold rating on Valeant Pharma (NYSE:VRX) shards via analysts note published on Wednesday, 9 May.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 13 analysts covering Valeant Pharmaceuticals International (NYSE:VRX), 2 have Buy rating, 4 Sell and 7 Hold. Therefore 15% are positive. Valeant Pharmaceuticals International has $25.0 highest and $10.0 lowest target. $16.22’s average target is -19.90% below currents $20.25 stock price. Valeant Pharmaceuticals International had 23 analyst reports since November 13, 2017 according to SRatingsIntel. The rating was maintained by Susquehanna on Thursday, March 8 with “Hold”. Piper Jaffray maintained it with “Sell” rating and $10.0 target in Thursday, March 1 report. H.C. Wainwright maintained it with “Hold” rating and $1600 target in Monday, May 7 report. Mizuho maintained it with “Underperform” rating and $10 target in Friday, December 15 report. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, May 2 report. J.P. Morgan downgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Thursday, December 14 to “Sell” rating. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Buy” rating by Cantor Fitzgerald on Friday, January 19. Piper Jaffray maintained the shares of VRX in report on Wednesday, May 9 with “Sell” rating. The firm has “Hold” rating given on Monday, February 26 by Canaccord Genuity. The firm earned “Hold” rating on Tuesday, January 16 by H.C. Wainwright.

The stock increased 2.43% or $0.48 during the last trading session, reaching $20.25. About 17.02M shares traded or 75.89% up from the average. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since May 10, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $7.06 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 2.96 P/E ratio. Diversified Products.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: which released: “Wednesday’s Vital Data: Valeant Pharmaceuticals Intl Inc (VRX), Walt Disney Co (DIS) and Citigroup Inc (C)” on May 09, 2018, also with their article: “Pre-Open Movers 05/08: (PI) (VRX) (FRED) Higher; (NVRO) (IONS) (AKCA) Lower (more…)” published on May 08, 2018, published: “4 Top Stock Trades for Wednesday Morning” on May 09, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: and their article: “Steve Sosnick’s Valeant Options Trade” published on May 04, 2018 as well as‘s news article titled: “Salix FDA Win Boosts Valeant Stock Before Earnings” with publication date: May 07, 2018.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: